Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival

Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 20; no. 19; pp. 5124 - 5132
Main Authors Dabir, Snehal, Kluge, Amy, Kresak, Adam, Yang, Michael, Fu, Pingfu, Groner, Bernd, Wildey, Gary, Dowlati, Afshin
Format Journal Article
LanguageEnglish
Published United States 01.10.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. Experimental design: We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells. Results: Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth. Conclusion: These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124–32. ©2014 AACR.
AbstractList Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling.PURPOSEDeregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling.We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.EXPERIMENTAL DESIGNWe evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.RESULTSGene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR.CONCLUSIONThese results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR.
Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells. Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth. These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR.
Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. Experimental design: We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells. Results: Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth. Conclusion: These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124–32. ©2014 AACR.
Author Fu, Pingfu
Kluge, Amy
Yang, Michael
Groner, Bernd
Wildey, Gary
Dabir, Snehal
Kresak, Adam
Dowlati, Afshin
Author_xml – sequence: 1
  givenname: Snehal
  surname: Dabir
  fullname: Dabir, Snehal
– sequence: 2
  givenname: Amy
  surname: Kluge
  fullname: Kluge, Amy
– sequence: 3
  givenname: Adam
  surname: Kresak
  fullname: Kresak, Adam
– sequence: 4
  givenname: Michael
  surname: Yang
  fullname: Yang, Michael
– sequence: 5
  givenname: Pingfu
  surname: Fu
  fullname: Fu, Pingfu
– sequence: 6
  givenname: Bernd
  surname: Groner
  fullname: Groner, Bernd
– sequence: 7
  givenname: Gary
  surname: Wildey
  fullname: Wildey, Gary
– sequence: 8
  givenname: Afshin
  surname: Dowlati
  fullname: Dowlati, Afshin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25124686$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1vGjEQtapUCaH5Ca187GWJv3dRTytEWiRQUKFny-v1Jo4Wm9oG2n9fbwmXHHKaGc17bzTv3YIr550B4DNGE4x5dY9RWRWIUTKZzX4WmBWYUPoBjDDnZUGJ4Fe5v2BuwG2MLwhhhhG7BjeEY8JEJUbguPQnuF7UGwrnf_bBxGi9g9bBlertk1MuwZWJPj2b3vqdgosI6xi9tiqZFp5seoYLp4NRMY-bbb2lsNbJHlUadJRr4dr7ANd5NllrcwjHvOw_gY-d6qO5e61j8Othvp39KJaP3xezelloykUqNKnaCrOumSpiCFOkLTnXFOUub5Dg3JSNapiasoZzQTsmSk46pqddft0QOgZfz7r74H8fTExyZ6M2fa-c8Ycos5MCTQXiPEO_vEIPzc60ch_sToW_8uJVBnw7A3TwMQbTSW3T_z9TULaXGMkhGTm4LgfXZU5GYiaHZDKbv2FfDrzP-wfyJ5C1
CitedBy_id crossref_primary_10_1039_C6RA25511F
crossref_primary_10_1158_1535_7163_MCT_14_0972
crossref_primary_10_4236_jct_2014_514136
crossref_primary_10_3390_cancers13174402
crossref_primary_10_1002_1878_0261_12386
crossref_primary_10_1016_j_biopha_2017_07_075
crossref_primary_10_1507_endocrj_EJ21_0106
crossref_primary_10_1038_s41467_018_04936_9
crossref_primary_10_1093_carcin_bgac089
crossref_primary_10_1016_j_phrs_2023_106915
crossref_primary_10_1146_annurev_genet_121415_121658
crossref_primary_10_1016_j_bcp_2021_114760
crossref_primary_10_1186_s12885_016_2063_1
crossref_primary_10_1158_0008_5472_CAN_17_1671
crossref_primary_10_1111_febs_13285
crossref_primary_10_1002_ajim_23062
crossref_primary_10_3389_fimmu_2016_00128
crossref_primary_10_1038_srep26524
crossref_primary_10_3389_fphar_2021_806570
crossref_primary_10_1002_1878_0261_12034
crossref_primary_10_3892_ol_2021_12892
crossref_primary_10_1111_jcmm_13786
crossref_primary_10_2174_1574892818666230803100554
crossref_primary_10_3390_cancers13010007
crossref_primary_10_4049_jimmunol_1403254
crossref_primary_10_1111_his_13154
crossref_primary_10_3390_nu8050275
crossref_primary_10_1016_j_bioorg_2023_106741
crossref_primary_10_1002_cbin_11399
crossref_primary_10_1074_jbc_M115_691170
crossref_primary_10_1002_jcp_25310
crossref_primary_10_1002_mc_23623
crossref_primary_10_1002_mc_22778
crossref_primary_10_1016_j_prp_2023_154947
crossref_primary_10_3390_biomedicines12092102
crossref_primary_10_1016_j_phrs_2017_12_034
Cites_doi 10.1016/j.ejca.2005.05.009
10.1593/neo.101156
10.1002/ijc.24553
10.1158/1541-7786.MCR-09-0417
10.1158/1541-7786.MCR-09-0313
10.1158/1078-0432.CCR-08-0618
10.1158/1541-7786.MCR-07-0245
10.1111/j.2517-6161.1972.tb00899.x
10.1038/bjc.2012.379
10.1038/nature11003
10.1517/14728222.8.5.409
10.1016/j.ejim.2011.04.002
10.4161/cbt.12.2.15732
10.1177/1947601910375273
10.1074/jbc.M104986200
10.1002/jcb.22558
10.1038/sj.onc.1204086
10.1158/1078-0432.CCR-04-1940
10.1593/neo.06409
10.1039/c3cc46931j
10.1126/science.278.5344.1803
10.1016/j.molonc.2011.03.004
10.1021/mp700113r
10.1200/JCO.2006.09.7634
10.1080/01621459.1958.10501452
10.1101/gad.1421006
10.1007/s00280-011-1655-3
10.1016/j.mehy.2013.09.022
10.2174/138945009789753200
10.5858/2007-131-1350-EOAALS
10.1056/NEJMra050152
10.1007/s40259-013-0058-x
10.1038/sj.cr.7310027
10.1016/j.canlet.2008.03.009
10.1172/JCI0215617
10.1073/pnas.1121606109
ContentType Journal Article
Copyright 2014 American Association for Cancer Research.
Copyright_xml – notice: 2014 American Association for Cancer Research.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1078-0432.CCR-14-1233
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 5132
ExternalDocumentID 25124686
10_1158_1078_0432_CCR_14_1233
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
QTD
RCR
RHI
RNS
SJN
TR2
W2D
W8F
WOQ
YKV
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
ID FETCH-LOGICAL-c356t-c28d814fb9a2e24a2d755c304a228d0655e7bab4a94b5563f46752f4c9f078e23
ISSN 1078-0432
1557-3265
IngestDate Fri Jul 11 00:16:23 EDT 2025
Wed Feb 19 02:29:41 EST 2025
Tue Jul 01 03:06:53 EDT 2025
Thu Apr 24 23:08:50 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 19
Language English
License 2014 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c356t-c28d814fb9a2e24a2d755c304a228d0655e7bab4a94b5563f46752f4c9f078e23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://clincancerres.aacrjournals.org/content/clincanres/20/19/5124.full.pdf
PMID 25124686
PQID 1586096055
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1586096055
pubmed_primary_25124686
crossref_citationtrail_10_1158_1078_0432_CCR_14_1233
crossref_primary_10_1158_1078_0432_CCR_14_1233
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-10-01
2014-Oct-01
20141001
PublicationDateYYYYMMDD 2014-10-01
PublicationDate_xml – month: 10
  year: 2014
  text: 2014-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2014
References Ogata (2022061107010404800_bib12) 2006; 8
Gordon (2022061107010404800_bib20) 2002; 62
Pasello (2022061107010404800_bib28) 2009; 10
Li (2022061107010404800_bib34) 2013; 81
Rocks (2022061107010404800_bib37) 2012; 107
Groner (2022061107010404800_bib1) 2014; 382
Cox (2022061107010404800_bib18) 1972; 34
Groner (2022061107010404800_bib40) 2014; 28
Borghouts (2022061107010404800_bib5) 2012; 1
Zhang (2022061107010404800_bib33) 2012; 109
Saydmohammed (2022061107010404800_bib24) 2010; 110
Bromberg (2022061107010404800_bib4) 2002; 109
Groner (2022061107010404800_bib2) 2012; 1
Kaplan (2022061107010404800_bib21) 1958; 53
Garland (2022061107010404800_bib32) 2007; 25
Turkson (2022061107010404800_bib6) 2004; 8
Jakobsen (2022061107010404800_bib27) 2011; 68
Kluge (2022061107010404800_bib14) 2011; 5
Borghouts (2022061107010404800_bib17) 2010; 8
Sharrocks (2022061107010404800_bib7) 2006; 20
Chung (2022061107010404800_bib9) 1997; 278
Robinson (2022061107010404800_bib26) 2005; 353
Anand (2022061107010404800_bib36) 2007; 4
Kluge (2022061107010404800_bib11) 2009; 125
Dabir (2022061107010404800_bib10) 2009; 7
Shuai (2022061107010404800_bib8) 2006; 16
Brantley (2022061107010404800_bib13) 2008; 14
Liu (2022061107010404800_bib35) 2011; 22
Turkson (2022061107010404800_bib3) 2000; 19
Dabir (2022061107010404800_bib15) 2011; 12
Achcar Rde (2022061107010404800_bib25) 2007; 131
Ou (2022061107010404800_bib30) 2011; 13
Li (2022061107010404800_bib39) 2014; 50
Barretina (2022061107010404800_bib19) 2012; 483
Govindan (2022061107010404800_bib31) 2005; 11
Menges (2022061107010404800_bib29) 2010; 1
Sharma (2022061107010404800_bib22) 2005; 41
Unkila (2022061107010404800_bib16) 2001; 276
Kunnumakkara (2022061107010404800_bib23) 2008; 269
Borghouts (2022061107010404800_bib38) 2008; 6
References_xml – volume: 41
  start-page: 1955
  year: 2005
  ident: 2022061107010404800_bib22
  article-title: Curcumin: the story so far
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2005.05.009
– volume: 13
  start-page: 12
  year: 2011
  ident: 2022061107010404800_bib30
  article-title: Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma
  publication-title: Neoplasia
  doi: 10.1593/neo.101156
– volume: 125
  start-page: 1728
  year: 2009
  ident: 2022061107010404800_bib11
  article-title: Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.24553
– volume: 1
  start-page: 44
  year: 2012
  ident: 2022061107010404800_bib5
  article-title: A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells
  publication-title: JAKSTAT
– volume: 8
  start-page: 539
  year: 2010
  ident: 2022061107010404800_bib17
  article-title: The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-09-0417
– volume: 7
  start-page: 1854
  year: 2009
  ident: 2022061107010404800_bib10
  article-title: The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-09-0313
– volume: 14
  start-page: 4694
  year: 2008
  ident: 2022061107010404800_bib13
  article-title: Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-0618
– volume: 6
  start-page: 267
  year: 2008
  ident: 2022061107010404800_bib38
  article-title: Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-07-0245
– volume: 34
  start-page: 187
  year: 1972
  ident: 2022061107010404800_bib18
  article-title: Regression Models and Life-Tables
  publication-title: J R Stat Soc Ser B-Stat Methodol
  doi: 10.1111/j.2517-6161.1972.tb00899.x
– volume: 107
  start-page: 1083
  year: 2012
  ident: 2022061107010404800_bib37
  article-title: Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.379
– volume: 382
  start-page: 551
  year: 2014
  ident: 2022061107010404800_bib1
  article-title: Molecular and cellular endocrinology: special issue on cytokine signaling
  publication-title: Mol Cell Endocrinol
– volume: 483
  start-page: 603
  year: 2012
  ident: 2022061107010404800_bib19
  article-title: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
  publication-title: Nature
  doi: 10.1038/nature11003
– volume: 8
  start-page: 409
  year: 2004
  ident: 2022061107010404800_bib6
  article-title: STAT proteins as novel targets for cancer drug discovery
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14728222.8.5.409
– volume: 22
  start-page: e31
  year: 2011
  ident: 2022061107010404800_bib35
  article-title: The expression of protein inhibitor of activated signal transducers and activators of transcription 3 in the evolutionary process of gastric cancer
  publication-title: Eur J Intern Med
  doi: 10.1016/j.ejim.2011.04.002
– volume: 12
  start-page: 139
  year: 2011
  ident: 2022061107010404800_bib15
  article-title: Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.12.2.15732
– volume: 62
  start-page: 4963
  year: 2002
  ident: 2022061107010404800_bib20
  article-title: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma
  publication-title: Cancer Res
– volume: 1
  start-page: 493
  year: 2010
  ident: 2022061107010404800_bib29
  article-title: A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma
  publication-title: Genes Cancer
  doi: 10.1177/1947601910375273
– volume: 1
  start-page: 211
  year: 2012
  ident: 2022061107010404800_bib2
  article-title: Determinants of the extent and duration of STAT3 signaling
  publication-title: JAKSTAT
– volume: 276
  start-page: 39132
  year: 2001
  ident: 2022061107010404800_bib16
  article-title: Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M104986200
– volume: 110
  start-page: 447
  year: 2010
  ident: 2022061107010404800_bib24
  article-title: Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.22558
– volume: 19
  start-page: 6613
  year: 2000
  ident: 2022061107010404800_bib3
  article-title: STAT proteins: novel molecular targets for cancer drug discovery
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204086
– volume: 11
  start-page: 2300
  year: 2005
  ident: 2022061107010404800_bib31
  article-title: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1940
– volume: 8
  start-page: 817
  year: 2006
  ident: 2022061107010404800_bib12
  article-title: Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation
  publication-title: Neoplasia
  doi: 10.1593/neo.06409
– volume: 50
  start-page: 6458
  year: 2014
  ident: 2022061107010404800_bib39
  article-title: Base-catalyzed bicyclization of dialkyl glutaconates with cinnamoylacetamides: a synthetic strategy for isoquinolinedione derivatives
  publication-title: Chem Commun
  doi: 10.1039/c3cc46931j
– volume: 278
  start-page: 1803
  year: 1997
  ident: 2022061107010404800_bib9
  article-title: Specific inhibition of Stat3 signal transduction by PIAS3
  publication-title: Science
  doi: 10.1126/science.278.5344.1803
– volume: 5
  start-page: 256
  year: 2011
  ident: 2022061107010404800_bib14
  article-title: Protein inhibitor of activated STAT3 expression in lung cancer
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2011.03.004
– volume: 4
  start-page: 807
  year: 2007
  ident: 2022061107010404800_bib36
  article-title: Bioavailability of curcumin: problems and promises
  publication-title: Mol Pharm
  doi: 10.1021/mp700113r
– volume: 25
  start-page: 2406
  year: 2007
  ident: 2022061107010404800_bib32
  article-title: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.7634
– volume: 53
  start-page: 457
  year: 1958
  ident: 2022061107010404800_bib21
  article-title: Nonparametric Estimation from Incomplete Observations
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1958.10501452
– volume: 20
  start-page: 754
  year: 2006
  ident: 2022061107010404800_bib7
  article-title: PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases?
  publication-title: Genes Dev
  doi: 10.1101/gad.1421006
– volume: 68
  start-page: 1
  year: 2011
  ident: 2022061107010404800_bib27
  article-title: Review on clinical trials of targeted treatments in malignant mesothelioma
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-011-1655-3
– volume: 81
  start-page: 1151
  year: 2013
  ident: 2022061107010404800_bib34
  article-title: PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2013.09.022
– volume: 10
  start-page: 1235
  year: 2009
  ident: 2022061107010404800_bib28
  article-title: Molecular targets in malignant pleural mesothelioma treatment
  publication-title: Curr Drug Targets
  doi: 10.2174/138945009789753200
– volume: 131
  start-page: 1350
  year: 2007
  ident: 2022061107010404800_bib25
  article-title: Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/2007-131-1350-EOAALS
– volume: 353
  start-page: 1591
  year: 2005
  ident: 2022061107010404800_bib26
  article-title: Advances in malignant mesothelioma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra050152
– volume: 28
  start-page: 27
  year: 2014
  ident: 2022061107010404800_bib40
  article-title: Targeting survivin in cancer: novel drug development approaches
  publication-title: Biodrugs
  doi: 10.1007/s40259-013-0058-x
– volume: 16
  start-page: 196
  year: 2006
  ident: 2022061107010404800_bib8
  article-title: Regulation of cytokine signaling pathways by PIAS proteins
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7310027
– volume: 269
  start-page: 199
  year: 2008
  ident: 2022061107010404800_bib23
  article-title: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.03.009
– volume: 109
  start-page: 1139
  year: 2002
  ident: 2022061107010404800_bib4
  article-title: Stat proteins and oncogenesis
  publication-title: J Clin Invest
  doi: 10.1172/JCI0215617
– volume: 109
  start-page: 9623
  year: 2012
  ident: 2022061107010404800_bib33
  article-title: Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1121606109
SSID ssj0014104
Score 2.3294551
Snippet Purpose: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined...
Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 5124
SubjectTerms Apoptosis - drug effects
Apoptosis - genetics
Cell Line, Tumor
Cell Proliferation - drug effects
Curcumin - pharmacology
Gene Expression
Humans
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Mesothelioma - genetics
Mesothelioma - metabolism
Mesothelioma - mortality
Mesothelioma, Malignant
Molecular Chaperones - chemistry
Molecular Chaperones - genetics
Molecular Chaperones - metabolism
Molecular Chaperones - pharmacology
Peptide Fragments - pharmacology
Prognosis
Protein Inhibitors of Activated STAT - chemistry
Protein Inhibitors of Activated STAT - genetics
Protein Inhibitors of Activated STAT - metabolism
Protein Inhibitors of Activated STAT - pharmacology
RNA Interference
RNA, Messenger - genetics
RNA, Small Interfering - genetics
STAT3 Transcription Factor - genetics
STAT3 Transcription Factor - metabolism
Title Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
URI https://www.ncbi.nlm.nih.gov/pubmed/25124686
https://www.proquest.com/docview/1586096055
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj5swELbSrVT1UvXd9CVX6i0iTYxN4IiyrXabtoc2K-0NGWNapACrkOyh2h-_M8YGWmXVxwUhLEPE92U8Y2a-IeRtHoRhxoPM07D6eFwo5kWwEnoLzQPfD2SeSaP2-SU4OeMfz8X5aHQ1rC7ZpVP182Bdyf-gCtcAV6yS_Qdku5vCBTgHfOEICMPxrzD-hHVsp_E3H4X624RWk7hYgnP9HTNcJqVusMRqU9SlxN7l0qLhks6LCr3GBr3Odbz2jbRGu0nbKgjU9dZJr06aPZiVS_ubnLiBK6xUyJ7txGoHdXvMxzIt2s5elf4hu2yO1WbftnSP-4KKFcyVxjbHmSw7a2T3s4fp_XaTYs67dDdYY6xhFWDMWNsXwlleNhsyLBrYUXBD-GEDL0Kz14C6wNxn0-Xyq4ePY62cxgD0i9Kgjv4bD36X2zYLuBu6RW4zCDKw_8Xx6ar7BsUhUrU1X_DUdwefiVrS9i6_OjY3RCvGa1nfJ_dsuEHjljsPyEhXD8mdzzah4hG5BApRQyHaU4gWFe0oRIcUokVDewpRpBDtKEQNhWhPIQoUokghailEHYUek7MP79fLE8-24vCUL4Kdp1iYhXOep5FkmnHJsoUQyp_BGYyAGyv0IpUplxFPUXIuh_VXsJyrKIfXppn_hBxVdaWfEboAnzaFuBlmSz5PwcWXTKpZmKl5ngeZGhPu3mOirE49tkvZJCZeFWGCSCSIRAJIQOyaIBJjMu2mXbRCLX-a8MaBlIBJxe9kstL1vklgSoCRvRBj8rRFr7ulQ_v5jSMvyN3-H_CSHO22e_0KHNdd-trw6xoqX5TG
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+PIAS3+expression+in+malignant+mesothelioma+is+associated+with+increased+STAT3+activation+and+poor+patient+survival&rft.jtitle=Clinical+cancer+research&rft.au=Dabir%2C+Snehal&rft.au=Kluge%2C+Amy&rft.au=Kresak%2C+Adam&rft.au=Yang%2C+Michael&rft.date=2014-10-01&rft.eissn=1557-3265&rft.volume=20&rft.issue=19&rft.spage=5124&rft_id=info:doi/10.1158%2F1078-0432.CCR-14-1233&rft_id=info%3Apmid%2F25124686&rft.externalDocID=25124686
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon